# Biohaven Therapeutics Ltd. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Biohaven Therapeutics Ltd. as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Biohaven Therapeutics Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/biohaven-therapeutics-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901244 | An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease | Biohaven Therapeutics Ltd. | Phase 2/3 | Not yet recruiting | Graves' Disease | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901244) |
| June 22, 2026 | NCT07661056 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | Biohaven Therapeutics Ltd. | Phase 3 | Recruiting | Graves Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661056) |
| June 11, 2026 | NCT07642050 | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy | Biohaven Therapeutics Ltd. | Phase 3 | Not yet recruiting | IgA Nephropathy | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642050) |
| December 15, 2025 | NCT07281495 | Taldefgrobep Alfa in Adults With Overweight and Obesity | Biohaven Therapeutics Ltd. | Phase 2 | Active not recruiting | Obesity, Overweight | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281495) |
| December 3, 2025 | NCT07262268 | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia | Biohaven Therapeutics Ltd. | Phase 1 | Active not recruiting | Familial Erythromelalgia | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262268) |
| July 8, 2025 | NCT07054684 | Study of BHV-1400 in IgA Nephropathy | Biohaven Therapeutics Ltd. | Phase 1 | Recruiting | IgA Nephropathy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07054684) |
| May 20, 2025 | NCT06980649 | Study of BHV-1300 in Graves' Disease | Biohaven Therapeutics Ltd. | Phase 1 | Recruiting | Graves Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980649) |
| May 16, 2025 | NCT06976268 | A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Biohaven Therapeutics Ltd. | Phase 2/3 | Recruiting | Parkinson Disease | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976268) |
| March 13, 2025 | NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Biohaven Therapeutics Ltd. | Phase 1 | Recruiting | Solid Tumor | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06874335) |
| September 19, 2024 | NCT06603623 | Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine | Biohaven Therapeutics Ltd. | Phase 2 | Completed | Migraine | 647 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06603623) |
| July 31, 2024 | NCT06529146 | Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control | Biohaven Therapeutics Ltd. | Observational | Completed | Spinocerebellar Ataxias | 909 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06529146) |
| June 5, 2024 | NCT06443463 | Long-term Safety and Tolerability of BHV-7000 | Biohaven Therapeutics Ltd. | Phase 2 | Enrolling by invitation | Focal Epilepsy | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06443463) |
| May 22, 2024 | NCT06425159 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | Biohaven Therapeutics Ltd. | Phase 2/3 | Terminated | Generalized Epilepsy | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06425159) |
| May 21, 2024 | NCT06423794 | BHV-7000 Open-Label Extension Bipolar Mania Study | Biohaven Therapeutics Ltd. | Phase 2 | Terminated | Bipolar Disorder | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423794) |
| May 21, 2024 | NCT06423781 | Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) | Biohaven Therapeutics Ltd. | Phase 2 | Completed | Major Depressive Disorder | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423781) |
| May 17, 2024 | NCT06419608 | Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | Biohaven Therapeutics Ltd. | Phase 2 | Completed | Major Depressive Disorder | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419608) |
| May 17, 2024 | NCT06419582 | BHV-7000 Acute Treatment of Bipolar Mania | Biohaven Therapeutics Ltd. | Phase 2/3 | Completed | Bipolar Disorder | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419582) |
| April 25, 2024 | NCT06384807 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Biohaven Therapeutics Ltd. | Phase 1/2 | Recruiting | Solid Tumor | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06384807) |
| March 13, 2024 | NCT06309966 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Biohaven Therapeutics Ltd. | Phase 2/3 | Active not recruiting | Focal Epilepsy | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06309966) |
| November 15, 2023 | NCT06132893 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Biohaven Therapeutics Ltd. | Phase 2/3 | Active not recruiting | Focal Epilepsy | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06132893) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 6 |
| Phase 3 | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 6 |
| Completed | 5 |
| Active not recruiting | 4 |
| Not yet recruiting | 2 |
| Terminated | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 4 |
| Seizures | 4 |
| Drug Resistant Epilepsy | 4 |
| Epilepsies, Partial | 3 |
| Graves Disease | 3 |
| Hyperthyroidism | 3 |
| Glomerulonephritis, IGA | 2 |
| Renal Insufficiency, Chronic | 2 |
| Kidney Diseases | 2 |
| Proteinuria | 2 |
| Nephritis | 2 |
| Urologic Diseases | 2 |
| Glomerulonephritis | 2 |
| Depressive Disorder, Major | 2 |
| Depression | 2 |
| Bipolar Disorder | 2 |
| Mania | 2 |
| Erythromelalgia | 1 |
| Generalized Epilepsy With Febrile Seizures Plus, 7 | 1 |
| Channelopathies | 1 |
| Neuralgia | 1 |
| Obesity | 1 |
| Overweight | 1 |
| Migraine Disorders | 1 |
| Spinocerebellar Ataxias | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
